Evaluation of the Q-Pad hrHPV Test System for Identifying Precancer
NCT07281599
This study is recruiting at 3 US sites in 3 states, according to its ClinicalTrials.gov record last updated .
Summary
The EQUIP Study is testing whether high-risk human papillomavirus (hrHPV), the virus that causes most cervical cancers, can be accurately detected from menstrual blood collected at home. People who have been referred for colposcopy after an abnormal Pap or hrHPV test will use the Q-Pad Kit during their period to collect menstrual samples on a special menstrual pad and mail them to a central laboratory for hrHPV testing. The same participants will have a standard cervical sample collected for routine hrHPV testing and will undergo colposcopy as part of their usual care.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- HPV Infection
- HPV 16 Infection
- High Risk HPV
- Cervical Cancer Screening
- Cervical Cancer Cin Grade
- Cervical Cancer (Early Detection)
- HPV
- HPV (Human Papillomavirus)-Associated
- HPV DNA
- HPV Infections
- Screening Test
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Not applicable
- Ages
- 25 years and older
- Sex
- Female
- Healthy volunteers
- Accepted
- Sponsor
- Qurasense
- Last updated on ClinicalTrials.gov
- July 24, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Connecticut · 1
- Planned Parenthood of Southern New England · New Haven, CT
Minnesota · 1
- Planned Parenthood North Central States · Minneapolis, MN
Ohio · 1
- Planned Parenthood of Greater Ohio (PPGOH) · Akron, OH
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.